The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.

Inclusion Criteria:

• Have 2 or more genital warts of prespecified sizes on external surfaces of the body.
• If HIV positive, have HIV RNA < 400 copies/mL, CD4 count of ≥ 400 cells/mm3, and be taking a triple combination antiviral medication regimen

Exclusion Criteria:

• Prior genital wart treatment within 8 weeks
• Pregnancy or breast-feeding
• Presence of broken or non-intact skin near the wart site or other skin disease at the wart site (e.g., herpes genitalis)
• Treatment with systemic steroids, systemic immunomodulators, immunosuppressants, or chemotherapeutic agents within 3 months
• Current or prior diagnosis of Bowenoid papulosis, cancer, or pre-cancerous tissue in the genital area